Equities Analysts Offer Predictions for RANI Q1 Earnings

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rani Therapeutics in a report issued on Friday, March 27th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Rani Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2030 earnings at ($0.30) EPS.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $5.00 million.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rani Therapeutics in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Rani Therapeutics Price Performance

Shares of NASDAQ RANI opened at $0.81 on Monday. The stock has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.32. Rani Therapeutics has a 1-year low of $0.39 and a 1-year high of $3.87. The company has a market cap of $98.50 million, a PE ratio of -1.37 and a beta of 0.39.

Institutional Trading of Rani Therapeutics

A number of institutional investors have recently modified their holdings of RANI. Jefferies Financial Group Inc. acquired a new position in Rani Therapeutics during the fourth quarter worth $40,000. Virtu Financial LLC acquired a new stake in Rani Therapeutics in the fourth quarter valued at $69,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Rani Therapeutics during the 4th quarter worth $93,000. Farallon Capital Management LLC purchased a new stake in shares of Rani Therapeutics during the 4th quarter worth $105,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Rani Therapeutics during the 4th quarter worth $155,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.